Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 811 of 5804
-
Mind-controlled devices: tiny brain chip tested in paralysis patients
Disease control Recruiting nowThe Bidirectional Cortical Neuroprosthetic System (BiCNS) consists of NeuroPort Microelectrode Array Systems and NeuroPort Electrodes (Sputtered Iridium Oxide Film), Patient Pedestals, the NeuroPort BioPotential Signal Processing System, and the CereStim C96 Programmable Stimulat…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 26, 2026 14:50 UTC
-
Microstent offers new hope for stubborn glaucoma
Disease control CompletedThe purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent in patients with refractory open-angle glaucoma.
Phase: NA • Sponsor: Ivantis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Own skin cells boost healing of diabetic foot ulcers in new trial
Disease control CompletedDiabetic foot ulcer is one of the refractory wounds and always poses many challenges in clinical practice. This study was conducted to have a prospective, randomised, controlled study compare the safety and efficacy of the autologous skin cell with skin graft (experiment group) w…
Phase: NA • Sponsor: Hu Zhicheng • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Gene therapy watch: 5-Year safety check for inherited blindness treatment
Disease control CompletedThis is a long-term follow-up study assessing safety of patients for up to 60 months following advanced therapy investigational medicinal product (ATIMP) AAV5-hRKp.RPGR vector in participants with XLRP caused by mutations in RPGR.
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo therapy aims to boost transplant success in tough leukemia cases
Disease control OngoingThis phase I/II trial studies the best dose of sorafenib when given together with busulfan and fludarabine in treating patients with acute myeloid leukemia that has come back or does not respond to treatment and who are undergoing donor stem cell transplant. Sorafenib may stop th…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Immunotherapy cocktail takes on deadly thyroid cancer
Disease control OngoingThis phase II trial studies how well atezolizumab in combination with chemotherapy works in treating patients with anaplastic or poorly differentiated thyroid cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the canc…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Your own cells could mend shattered bones in breakthrough trial
Disease control Recruiting nowThe purpose of this clinical study is to evaluate the safety and the efficacy of BonoFill-II as an autologous bone-regenerating graft in the reconstruction of deficient bone in two clinical indications: 1. Long and short bone extra-articular comminuted fracture 2. Long and short…
Phase: PHASE1, PHASE2 • Sponsor: BonusBio Group Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Targeted radiation shows promise for Hard-to-Treat blood cancers
Disease control OngoingPart A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), margina…
Phase: PHASE2 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for rare kidney cancer: targeted drug savolitinib faces off against standard therapy
Disease control OngoingThis study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is effective in treating patients with…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Brain zaps and therapy show promise for kids with stroke paralysis
Disease control CompletedPerinatal stroke causes lifelong neurological disability and most hemiparetic cerebral palsy (CP). With morbidity spanning diverse aspects of a child's life and lasting for decades, global impact is large, including 10000 Canadian children. With pathophysiology poorly understood …
Phase: NA • Sponsor: University of Calgary • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Spared brain region may shield memory during whole brain radiation
Symptom relief OngoingThis is a trial that evaluates the preservation of cognition and neuropsychiatric function following genu-sparing whole brain radiation in patients with brain metastases.
Phase: NA • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Can a new pill tame GVHD after transplant?
Disease control CompletedThe purpose of this study is to evaluate itacitinib or placebo in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 26, 2026 13:19 UTC
-
Breathing easy: inhaled antibiotic may stop ventilator pneumonia
Prevention CompletedThe objective of the study is to prove that after the third day of invasive mechanical ventilation a three-day course of inhaled amikacin reduces the incidence of subsequent VAP. Parallel two group double blind randomized controlled clinical trial. Individual randomization, perf…
Phase: PHASE3 • Sponsor: University Hospital, Tours • Aim: Prevention
Last updated Jun 27, 2026 08:06 UTC
-
New combo therapy aims to boost immune attack on kidney cancer
Disease control OngoingThis randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body. Biological therapies, such as anti-OX40 antibody PF-04518600, use substances made from …
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Virus therapy takes on brain cancer in early trial
Disease control OngoingThis research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a …
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo targets Hard-to-Treat melanoma
Disease control OngoingThe goal of this clinical research study is to learn if GSK2636771 given in combination with pembrolizumab can help to control the disease in patients with refractory (has not responded to treatment) metastatic melanoma. The safety of this drug combination will also be studied. …
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug shows promise in taming psoriatic arthritis flares
Disease control CompletedThe primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immunotherapy combo before chemo-radiation shows promise for esophageal cancer
Disease control OngoingAnti-PD-1 (nivolumab) or Anti-PD1/Anti LAG-3- (relaltimab) administration in the pre-operative setting with chemoradiation will be safe and feasible in patients with resectable distal esophageal/gastroesophageal junction cancer and will change cellular and molecular characteristi…
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for young AML patients: epigenetic drugs plus chemotherapy show promise
Disease control CompletedThis is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).
Phase: PHASE1 • Sponsor: Therapeutic Advances in Childhood Leukemia Consortium • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Engineered immune cells show promise against hard-to-treat leukemia
Disease control OngoingThis is a single-arm, open-label, single-center, phase I/II study to determine the safety and efficacy of CD19 CAR-T(ssCART-19) combined with autologous T cells engineered to express CD19, namely CD19+ feeding T cells (FTCs), as consolidation therapy in patients diagnosed with de…
Phase: PHASE1, PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC